On November 18, 2026 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported positive preliminary clinical data from the Phase 1 portion of the Phase 1/2 AVENTINE-1 study evaluating AVZO-1418 in patients with locally advanced or metastatic solid tumors. The data highlight the pan-tumor potential of AVZO-1418 with objective responses observed across five of eight tumor types. Preliminary efficacy data also showed an objective response rate (ORR) of 63% in 19 evaluable patients with heavily pretreated epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the majority of whom were in 3rd line or later. AVZO-1418 also demonstrated a favorable safety profile with a low incidence of Grade 3/4 hematologic adverse events. The data are being presented as a poster at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium in Barcelona, Spain, on November 18, 2026, from 12:00 p.m. to 7:00 p.m. CET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AVZO-1418 has shown encouraging preliminary activity across multiple tumor types, pointing to its potential as a pan-tumor therapy," said Dr. Stephen Liu, Division Chief of Hematology/Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute. "I am especially encouraged by the strong efficacy signal and tolerability of AVZO-1418 in patients with EGFR-mutant NSCLC, the majority of whom received a prior 3rd generation EGFR TKI and platinum-based chemotherapy and have limited next options."
Clinical Data for AVENTINE-1, Phase 1/2 Study of AVZO-1418
As of the October 19, 2026 data cutoff, 61 patients with advanced solid tumors had received AVZO-1418 in the Phase 1 dose-escalation and backfill portion of the Phase 1/2 AVENTINE-1 study at doses of 2 to 6 mg/kg every two weeks (Q2W) or 6 mg/kg every three weeks (Q3W).
Patients included those with NSCLC-wild-type (NSCLC-WT) (n=20), EGFR-mutant NSCLC (EGFRm NSCLC) (n=19), colorectal cancer (CRC) (n=6), biliary tract cancer (BTC) (n=4), squamous cell carcinoma of the head and neck (SCCHN) (n=4), urothelial cancer (UC) (n=3), and other solid tumors (n=5). The backfill portion of the study was enriched for EGFRm NSCLC based on the strong early efficacy signal.
All patients (n=61) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 6), with 41% having received two prior lines of systemic therapy and 34% having received three or more prior lines. 84% of patients had received platinum-based chemotherapy and 54% had received anti-PD-(L)1 immunotherapy.
Patients with EGFRm NSCLC (n=19) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 4), with 47% having received two prior lines of systemic therapy and 16% having received three or more prior lines. 58% of patients had received platinum-based chemotherapy and all had received a prior 3rd generation EGFR tyrosine kinase inhibitor (TKI). At baseline, 63% of patients had an exon 19 deletion and 32% had an exon 21 L858R mutation.
Preliminary Safety Results
The overall safety population included 61 patients, with 48 patients treated at 2 to 5.5 mg/kg Q2W dose levels and 13 patients treated at 6 mg/kg Q2W and Q3W dose levels.
AVZO-1418 was generally well tolerated in the 2 to 5.5 mg/kg Q2W group (n=48)
No dose-limiting toxicities (DLTs) were observed.
Treatment-emergent adverse events (TEAEs) reported in >20% of patients were nausea, alopecia, fatigue, anemia, vomiting, stomatitis, headache, constipation, and decreased appetite. The majority of these events were Grade 1 or 2.
Anemia and neutrophil count decreased were reported as TEAEs in 33% and 19% of patients, with Grade 3/4 events reported in 4% and 6%, respectively.
Prophylactic granulocyte colony-stimulating factor (G-CSF) was not required in the study.
The 6 mg/kg dose level, dosed by actual body weight, exceeded the maximum tolerated dose (MTD) on both the Q2W and Q3W schedules, with two DLTs reported in each cohort.
Preliminary Efficacy Results
Preliminary efficacy data were available for 48 evaluable patients with measurable disease at baseline and at least one evaluable post-baseline scan. An additional seven patients remained on treatment and had not yet reached a post-baseline scan at the data cutoff date, and six patients were off treatment prior to an evaluable post-baseline scan for reasons other than disease progression.
Data are as of the cutoff date of October 19, 2026, with efficacy follow-up through November 5, 2026.
Responses were assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORRs reported below include confirmed partial responses and unconfirmed partial responses in patients who remain on treatment awaiting confirmatory scans.
Preliminary efficacy results across all tumor types suggest pan-tumor potential (n=48)
Responses were observed across six dose levels in five of eight tumor types (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT).
ORR was 38% (18 of 48 patients; 95% confidence interval (CI), 24.0%–52.6%), including 16 patients with confirmed partial responses (one patient with CRC confirmed their response after the efficacy follow up date), and two patients with unconfirmed partial responses who remained on treatment awaiting confirmatory scans.
26 of 48 patients remained on treatment as of the data cutoff date, including 17 of 18 responders.
13 patients had been on treatment for 24 weeks or longer.
Strong efficacy signal in patients with EGFRm NSCLC, majority of whom were previously treated with both a 3rd generation EGFR TKI and platinum-based chemotherapy (n=19)
ORR was 63% (12 of 19 patients; 95% CI, 38.4%–83.7%), including 10 patients with confirmed partial responses and two with unconfirmed partial responses who remained on treatment awaiting confirmatory scans, with multiple responses for 24 weeks or longer.
100% of patients achieved tumor reduction on their first post-baseline scan.
15 of 19 patients remained on treatment as of the data cutoff date, including:
11 responders.
Four patients with tumor reductions (three with >20% reduction from baseline) awaiting their next scans.
Responses were observed across five dose levels.
"We believe the preliminary data for AVZO-1418, with responses in five of eight tumor types, support its potential as a broadly active, pan-tumor therapy," said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. "We’re particularly excited by the strong signal in EGFR-mutant NSCLC, where patients urgently need new treatment options. We are pursuing a rapid development plan that includes global expansion and further evaluation in multiple tumor types, with the goal of bringing this potentially transformative therapy to patients as quickly as possible."
About AVZO-1418
AVZO-1418 is a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC) in development for locally advanced or metastatic solid tumors. It is designed with higher binding affinity for HER3 than EGFR to enhance delivery of its topoisomerase I inhibitor payload to EGFR/HER3-expressing tumors while limiting effects on healthy tissue. This dual-targeting approach may support activity across multiple tumor types, including EGFR-mutant non-small cell lung cancer. AVZO-1418 is being evaluated as monotherapy in the Phase 1 portion of the Phase 1/2 AVENTINE-1 study, with combination regimens also planned. Avenzo holds exclusive global rights, excluding Greater China, from DualityBio to develop, manufacture and commercialize AVZO-1418.
(Press release, Avenzo Therapeutics, NOV 18, 2026, View Source [SID1234674908])